Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Sponsor: Chongqing University Cancer Hospital
Summary
This is a phase 2, single-arm clinical trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 Blockade camrelizumab combined with induction chemotherapy followed by concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck squamous cell carcinoma.
Official title: A Phase II Trial of Induction and Adjuvant Camrelizumab Combined With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2022-01-01
Completion Date
2027-01-01
Last Updated
2023-05-06
Healthy Volunteers
No
Conditions
Interventions
Camrelizumab
200 mg, intravenous infusion over 30 minutes (Q3W); 1\~3 cycles of camrelizumab before radiotherapy and camrelizumab are maintained for 16 cycles (1 year) after the end of radiotherapy.
Concurrent cisplatin chemotherapy
cisplatin is given at a dose of 40 mg/m2 via intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy every week for 6 cycles.
Intensity-modulated radiotherapy (IMRT)
70 Gy/ 35 fractions/7 weeks, 5 fractions/week, 1 fraction/day.
Locations (3)
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Chongqing University Three Gorges Hospital
Wanzhou, Chongqing Municipality, China
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China